The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HCWB | -75.73% | N/A | N/A | -99% |
| S&P | +13.19% | +87.83% | +13.42% | +56% |
HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade chronic inflammation as a contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.02M | -96.3% |
| Gross Profit | -$0.17M | -295.7% |
| Gross Margin | -1094.35% | -1084.2% |
| Market Cap | $7.96M | -61.0% |
| Market Cap / Employee | $0.22M | 0.0% |
| Employees | 36 | -20.0% |
| Net Income | -$4.55M | -16.7% |
| EBITDA | -$3.11M | -19.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.10M | 9.9% |
| Accounts Receivable | $0.03M | -95.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.69M | -89.3% |
| Short Term Debt | $6.81M | 7.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -85.40% | 34.7% |
| Return On Invested Capital | -1033.30% | -971.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.24M | -9.3% |
| Operating Free Cash Flow | -$3.24M | -10.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.93 | -1.48 | -0.52 | -152.83 | 7368.21% |
| Price to Sales | 7.35 | 8.72 | 8.47 | 19.81 | 239.53% |
| Price to Tangible Book Value | -67.70 | -74.24 | -0.52 | -152.82 | 17.97% |
| Enterprise Value to EBITDA | -11.98 | -7.74 | -4.34 | -4.74 | -61.52% |
| Return on Equity | -344.3% | -537.2% | -897.4% | -27725.8% | 20832.04% |
| Total Debt | $13.69M | $13.94M | $8.54M | $7.50M | -41.42% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
